Long-term clinical trials of biologics in plaque psoriasis demonstrate heterogeneous study designs

Abstract

Numerous network meta-analyses have provided comparative efficacy and safety data for treatments in psoriaasis over a short period (8-24 weeks). So, we conducted a systematic review to map the design and synthesize all 1-year efficacy and safety data of biologic treatments for moderate-to-severe psoriasis from the randomized controlled trials (RCTs) included in the Cochrane review (Sbidian et al., 2022). Among the 81 RCTs included, many different designs are presented after the induction phase. Within a single trial, each arm (placebo, intervention, active comparator) could have a different design: single randomization; crossover; re-randomization. In addition, there was selection of patients into each arm based on the level of PASI response achieved or PGA achieved.

Characteristics and sources of tissue-resident memory T cells in psoriasis relapse

“…The expression levels of Fabp4 and Fabp5 in Trm are up-regulated, enhancing the lipid uptake capacity of Trm. In contrast, Fabp4/Fabp5-deficient mice exhibit significantly downregulated Trm levels and are more susceptible to viral infections [ Grolleau et al, 2023 ]. The immune function of CD8 + Trm is equally dependent on the uptake of exogenous fatty acids [ Pan, Y et al, 2017 ].…”

“…In recent years, biologics have significantly increased the effectiveness and safety of psoriasis treatment [ Grolleau et al, 2023 ]. However, the problem of psoriasis recurrence remains unresolved [ Puig, L et al, 2022 ].…”

“…Studies in immunology and genetics have confirmed the key role of TNF-α, IL-17 and IL-23 in the pathogenesis of psoriasis. Biologics that target TNF-α, IL-17 and IL-23 are now widely employed in clinical practice, and have achieved promising therapeutic results [ Grolleau et al, 2023 ]. However, a significant concern arises as the majority of patients often experience relapse after discontinuing therapy upon clinical cure [ Puig, L et al, 2022 ].…”